Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cationic liposome-mediated gene transfer

X Gao1, L Huang

  • 1Department of Pharmacology, University of Pittsburgh School of Medicine, PA 15261, USA.

Gene Therapy
|December 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The extra- and intracellular barriers to lipid and adenovirus-mediated pulmonary gene transfer in native sheep airway epithelium.

Gene therapy·1999
Same author

Liposome-mediated NGF gene transfection following neuronal injury: potential therapeutic applications.

Gene therapy·1999
Same author

A novel T7 RNA polymerase autogene for efficient cytoplasmic expression of target genes.

Gene therapy·1999
Same author

Regulation of F-actin binding to platelet moesin in vitro by both phosphorylation of threonine 558 and polyphosphatidylinositides.

Molecular biology of the cell·1999
Same author

A genetically modified recombinant tumor necrosis factor-alpha conjugated to the distal terminals of liposomal surface grafted polyethyleneglycol chains.

International journal of pharmaceutics·1999
Same author

Separation of nucleotide oligomers by unitary anion-exchange.

Journal of chromatographic science·1999
Same journal

Improving the precision of AAV lung gene therapy for SP-B deficiency using computationally derived lung-specific promoters.

Gene therapy·2026
Same journal

Recent advancements in improving cross-species applicability of bioengineered AAV capsids.

Gene therapy·2026
Same journal

Assessment of F/HN-pseudotyped lentiviral vector following intravenous delivery to mice.

Gene therapy·2026
Same journal

Applications of genome editing technologies in the treatment of human diseases.

Gene therapy·2026
Same journal

High resolution ES-DMA quantifies AAV capsid DNA content by electrical mobility to mass correlation.

Gene therapy·2026
Same journal

AAV8-mediated mouse/human PROC expression rescues thrombophilia in hereditary protein C-deficient mice.

Gene therapy·2026
See all related articles

Cationic liposomes are effective and safe non-viral vectors for direct gene transfer, enabling efficient DNA delivery for human gene therapy applications. Their ability to condense DNA and facilitate cell entry makes them promising for treating genetic diseases.

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Gene Therapy

Background:

  • Direct gene transfer necessitates safe and efficient vectors for treating human diseases.
  • Cationic liposomes are a promising class of non-viral vectors for gene delivery.

Purpose of the Study:

  • To evaluate cationic liposomes as efficient, safe, and repeatable vectors for direct gene transfer in human diseases.
  • To highlight the mechanism and clinical potential of cationic liposomes in gene therapy.

Main Methods:

  • Complexation of DNA with cationic liposomes to form stable nanoparticles.
  • Investigation of cellular uptake via endocytosis and endosomal escape mechanisms.
  • Assessment of safety and efficacy in preclinical and clinical studies.

Related Experiment Videos

Main Results:

  • Cationic liposomes efficiently bind and condense DNA, forming complexes with high cell membrane affinity.
  • Endocytosis followed by endosomal membrane disruption is the primary gene delivery mechanism.
  • Numerous studies confirm the effectiveness and safety of this DNA delivery method.

Conclusions:

  • Cationic liposomes are an attractive vehicle for human gene therapy due to their simplicity, efficiency, and safety.
  • Two human gene therapy clinical trials have been completed, with more anticipated, underscoring their clinical viability.